Company Description
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders.
The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial.
It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence.
The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.
| Country | United States |
| Founded | 2020 |
| IPO Date | Aug 3, 2023 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Erez Aminov |
Contact Details
Address: 1200 Brickell Avenue, Suite 1950 #1183 Miami, Florida 33131 United States | |
| Phone | 786 432 9792 |
| Website | mirapharmaceuticals.com |
Stock Details
| Ticker Symbol | MIRA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $7.00 |
| CIK Code | 1904286 |
| CUSIP Number | 60458C104 |
| ISIN Number | US60458C1045 |
| Employer ID | 85-3354547 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Erez Aminov | Chief Executive Officer and Chairman |
| Andriy Mushak CPA | Chief Financial Officer |
| Dr. Itzchak Angel Ph.D. | Chief Scientific Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 17, 2026 | 8-K | Current Report |
| Sep 16, 2026 | 8-K | Current Report |
| Sep 1, 2026 | 8-K | Current Report |
| Aug 12, 2026 | 10-Q | Quarterly Report |
| Aug 6, 2026 | 8-K | Current Report |
| Jul 31, 2026 | 8-K | Current Report |
| Jul 28, 2026 | DEF 14A | Other definitive proxy statements |
| Jul 10, 2026 | 8-K | Current Report |
| Jul 6, 2026 | 8-K | Current Report |
| Jun 25, 2026 | 8-K | Current Report |